Responding to an FDA warning--geographic variation in the use of rosiglitazone.
about
State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warningComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesIdentifying plausible adverse drug reactions using knowledge extracted from the literatureGeographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans AffairsAmbulatory treatment of type 2 diabetes in the U.S., 1997-2012.Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)Association between unemployment rates and prescription drug utilization in the United States, 2007-2010.The pragmatist's guide to comparative effectiveness researchUtilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.Rosiglitazone use and associated adverse event rates in Canada: an updated analysisImpact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.Variation in medication adherence in heart failureDisparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series studyRosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer.Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents.Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.Getting out of a sticky situation: targeting the myofibroblast in sclerodermaDrug vs class-specific black box warnings: does one bad drug spoil the bunch?Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills.Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.Rosiglitazone: trials, tribulations and termination.
P2860
Q24604853-D9D78EA6-C585-4BD6-9DDC-185A14C24496Q24632655-E6532D78-903F-4D34-9CCA-A27CCDAFA865Q28650098-7EA3594E-259B-4410-9C8D-C55A4B3EA5A9Q30359158-EE6F876A-3F39-46AE-A7F9-24EBB8350AACQ34259412-26E0F8CB-28DC-4DC1-9FC1-4549BE62C9DBQ34389980-97D305B0-03A0-42DC-9ED5-757F945A38B5Q34495367-85F5651E-6F95-425E-8D0C-EB942924727BQ35030741-3FAD0547-9463-450D-9388-BB4B85C6305CQ35141084-2399EFAB-A4F9-4EBB-82E6-12BAC8ACD793Q35792497-76C6019E-CF12-43B3-8D2A-4721631F9ED9Q35928690-68ADA272-5B63-41D2-8445-4C4E28940ED9Q36419283-BAA71C78-8648-42AD-A846-03F8C961FC29Q36486802-6B6B9AAA-74EE-4A22-BD94-ABB6344EFCD8Q36721701-5BCDE478-BD1B-48AB-93E7-395B54EB13C3Q36728428-492BF67F-E876-4E23-BC02-84A0A625AEE8Q36954288-19F62A73-FABA-492C-B77D-1D3DE966669BQ37185836-8120517D-2273-43E5-A1B4-37EBA17E7536Q37208292-F793A4AB-555B-475A-A38F-67E87F658E74Q37545937-78ED1C05-F299-4828-A287-60994101ACE0Q37699907-D8819EE1-EB67-4EA6-8146-22CC48FBA5B6Q38807857-7B92A930-3629-4B37-95A9-3D20252E5334Q39529503-AE55CA28-C574-429A-A0FC-40AC2709F423Q39711572-5838C430-D793-40FD-AC75-E770D060592DQ40649706-40CDD032-B456-47D5-B3CD-6DA12F3E31ABQ41816319-E47E2FDE-CA38-4731-9B91-BFDEAEC54493Q42739202-607D304B-C2E7-4DB6-9730-9834600B971FQ46643138-47907A7D-87D8-4BD6-884F-46EC3EEE0460Q47609958-09DBBB63-C7D7-426B-B556-7D7384B321C7Q47653552-96862FD7-1919-4C4B-9B51-600009365BCCQ53052728-AF1958FE-E07A-41D6-9B23-484291253BDA
P2860
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@en
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@nl
type
label
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@en
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@nl
prefLabel
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@en
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@nl
P2093
P356
P1476
Responding to an FDA warning--geographic variation in the use of rosiglitazone.
@en
P2093
Cynthia A Jackevicius
G Caleb Alexander
Nilay D Shah
P304
P356
10.1056/NEJMP1011042
P407
P577
2010-11-17T00:00:00Z